Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells

Chinese Journal of Cancer

Volumn 29, Issue 12, 2010, Pages 1006-1011

  Chen, Yong ^a   Zuo, Jing ^a   Liu, Ying ^a   Gao, Hong ^a   Liu, Wei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Bax; Bcl 2; Drug resistance; E cadherin; miRNA 200c; Proliferation

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MICRORNA; MICRORNA 200C; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MTT ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

EID: 79955801336     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.010.10236     Document Type: Article

References (22)

1. Chen Y, Zuo J, Liu W. miRNA-mediated biological behavior changes of tumors [J]. Chin J Cancer Biother, 2010, 17 (1): 109-114. [in Chinese]
2. Chen Y, Liu W. Progression of anti-tumor drugs sensitivity influenced by microRNA [J]. Chin Clin Oncol, 2009, 14 (9): 860-863. [in Chinese]
3. Korpal M, Kang Y. The emerging role of miR-200 family of miRNAs in epithelial-mesenchymal transition and cancer metastasis [J]. RNA Biol, 2008, 5(3): 115-119.
4. Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the MiRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin [J]. Cancer Res, 2007, 67(17): 7972-7976.
5. Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents [J]. Mol Cancer Ther, 2009, 8 (5): 1055-1066.
6. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy [J]. Clin Cancer Res, 2009, 15(16): 5060-5072.
7. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells [J]. Int J Cancer, 2010, 126(11): 2575-2583.
8. Cui XY, Guo YJ, Yao HR. Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR [J]. J South Med Univ, 2008, 28(10): 1813-1815. [in Chinese]
9. Li Y, Vanden Boom TG 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells [J]. Cancer Res, 2009, 69(16): 6704-6712.
10. Song KY, Sun JZ, Li K, et al. The difference of E-cadherin expression between breast cancer sensitive and resistant cell lines [J]. Chin J Cancer, 2001, 20(8): 889-890. [in Chinese]
11. Selga E, Morales C, Noé V, et al. Role of Caveolin 1, E-Cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells [J]. BMC Med Genomics, 2008, 1: 35.
12. Sasaki CY, Lin H, Passaniti A. Expression of E-cadherin reduces Bcl-2 expression and increases sensitivity to etoposide-induced apoptosis [J]. Int J Cancer, 2000, 86(5): 660-666.
13. Chen Y, Zuo J, Liu Y, et al. Reversion of the resistance of gastric cancer SGC7901/DDP cells by miRNA-200c its related mechanisms [J]. Tumor, 2010, 30(8): 646-650. [in Chinese]
14. St Croix B, Sheehan C, Rak JW, et al. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1) [J]. J Cell Biol, 1998, 142(2): 557-571.
15. Li Z, Wang L, Zhang W, et al. Restoring E-cadherin-mediated cell-cell adhesion increases PTEN protein level and stability in human breast carcinoma cells [J]. Biochem Biophys Res Commun, 2007, 363(1): 165-170.
16. Han Z, Hong L, Han Y, et al. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax [J]. J Exp Clin Cancer Res, 2007, 26(2): 261-268.
17. Chen ZY, Liang WT, Niu ZY, et al. Regulationary of PTEN/PI3K/Akt Pathway on Apoptosis of K562 Cells [J]. Cancer Res Prevention Treatment, 2009, 36(10): 828-832. [in Chinese]
18. Lee S, Choi EJ, Jin C, et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line [J]. Gynecol Oncol, 2005, 97(1): 26-34.
19. Wu HJ, Wu HT, Weng DH, et al. Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms [J]. Chin J Obstet Gynecol, 2007, 42(9): 612-616. [in Chinese]
20. Bouali S, Chrétien AS, Ramacci C, et al. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/ RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells [J]. Oncol Rep, 2009, 21(3): 731-735.
21. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer miR-214 induces cell survival and cisplatin resistance by targeting PTEN [J]. Cancer Res, 2008, 68 (2): 425-433.
22. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin [J]. Gene Ther, 2003, 10(19): 1636-1642.